about
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effectPhase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.Phase II study of sunitinib as second-line treatment for advanced gastric cancer.Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases.Pulmonary tumor thrombotic microangiopathy associated with esophageal squamous cell carcinoma.Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial.Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors.Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer.A phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumorsSafety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumorsPhase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylatePhotodynamic therapy as salvage treatment for local failure after chemoradiotherapy in patients with esophageal squamous cell carcinoma: a phase II study.Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors.Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.A multicenter retrospective study of endoscopic resection for early gastric cancer.Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.Phase I study of olaratumab in Japanese patients with advanced solid tumors.Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumorsA retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.A phase ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas.Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic methodPhase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors.Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial.Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials.Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma.Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors.Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer.Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer.Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA studyA phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer.Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer.Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumorsSafety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer.A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer.Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma.A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors.Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer.
P50
Q27853010-85376833-55C5-41C5-95E5-C9066E5394D7Q28542007-9F2959C1-52F3-46BD-B155-FED5618913FCQ33371147-FF19E609-9BEC-493F-949E-71671BC4717FQ33389519-111025D4-1FC5-49B7-A91F-6F6D22DB1ABFQ33394763-7F6A5FFE-E72D-4BDF-BACC-F9120F31EC29Q33398232-DAC62101-D20A-4BD9-A74E-7EE9FFD9F116Q33399121-E53DC0C9-7295-45B9-A8A3-8C6052F00D3BQ33402421-473774BB-A89D-49F8-AC26-B861F153AE76Q33420495-5B1D58C1-8A60-44CB-A98B-2A3845B4BFC7Q33431483-6C662CBA-57E3-4AC5-8E9F-AE8A161575D4Q33441667-7DEBB115-073C-43F2-AB39-8B73D3D4883FQ33566872-7BE182BD-5261-4438-970F-A2C9E058AE67Q33666010-52845169-CDF1-4E2C-98C0-19B7B06CD6A6Q34056960-9D174F93-B052-4F58-8A79-363C0C894625Q34085148-8FE478D4-7E5A-40BA-9AF5-1BA0BAB958A7Q34165276-15ABA323-63E8-403F-83F2-0D833EB60C52Q34574184-01D949F0-68F1-4B04-BF65-B63D4C06611EQ34662946-57CBE2D5-57F1-4E80-ACBA-6E39C38404BAQ35051852-81BBF533-49DA-41E8-915B-B192A2D86823Q35051964-5047C6CF-8973-4653-8057-960A3979E6F3Q35368335-9FA172B9-2730-42F2-AB43-B6C0B18C95EAQ35586723-8B32A13A-5781-4820-A9E0-2B6980659BE7Q35811012-25C63A30-F344-49C4-9946-AB4944F858AEQ35889628-55828BDA-AF9A-43C6-88D8-6C388419B655Q35925256-43AEB8D7-1029-46FD-9D1B-D7F191B31BB2Q36192000-02873A01-AA5A-4E7C-9549-C4674BEE952DQ36244592-9ADEACA1-A426-45F5-83CB-F9C9F055D4A3Q36503472-53D3768B-E865-4C9E-8A7A-05CBBF6D755DQ36621566-66990987-9DBE-4F5E-8B55-933659951AD5Q36625694-F9816424-318E-488D-8B74-69CCE2856F84Q36767776-FF304D0E-2A62-407F-AEC5-684604A3C494Q37028989-A515C5A0-AA12-4FA6-A665-40893CA89462Q37121517-D45FFC98-74CF-427C-8B67-098E8735C3B2Q37146675-9CD5CF77-D41A-4567-A46B-F584E5011268Q37157346-0C65EDD3-E3A9-4237-9B9E-09A2323324B0Q37222790-9E4C5038-4358-4331-9BF4-6B9FD23C85BEQ37415106-8B5C483E-0B85-48C8-9AC2-CFABCDD94190Q37565108-CBB3CE71-CDFC-476F-8383-F7BD90846F89Q37578324-10EDEFA5-C0E0-42BD-B943-23B1EF26034DQ37709811-3D01B01B-3551-401D-BA41-634C36A8A61A
P50
name
Toshihiko Doi
@en
Toshihiko Doi
@nl
type
label
Toshihiko Doi
@en
Toshihiko Doi
@nl
prefLabel
Toshihiko Doi
@en
Toshihiko Doi
@nl